- Home
- DTIL vs RFL Comparison
DTIL vs RFL Comparison
Compare DTIL & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DTIL | RFL |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 61.1M |
| IPO Year | 2019 | 2017 |
Fundamental Metrics
Financial Performance| Metric | DTIL | RFL |
|---|---|---|
| Price | $4.73 | $1.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $60.00 | N/A |
| AVG Volume (30 Days) | ★ 158.4K | 89.3K |
| Earning Date | 03-31-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 106.52 | 28.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,070,000,000.00 | $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $34.30 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $3.53 | $1.12 |
| 52 Week High | $8.82 | $3.19 |
Technical Indicators
Market Signals| Indicator | DTIL | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 63.59 | 71.85 |
| Support Level | $4.66 | $1.41 |
| Resistance Level | $5.19 | $1.64 |
| Average True Range (ATR) | 0.28 | 0.10 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 76.34 | 73.17 |
Price Performance
Historical ComparisonAbout DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.